Comparing an Early Corticosteroid/Late Calcineurin-Free Immunosuppression Protocol to a Sirolimus-, Cyclosporine A-, and Prednisone-Based Regimen for Pancreas-Kidney Transplantation

Aim. A prednisone and calcineurin inhibitor (CNI)-free protocol was compared with a sirolimus, cyclosporine A (CsA), and prednisone-based immunosuppressive regimen for simultaneous pancreas-kidney transplantation (SPK). Methods. A nonrandomized, single-center, sequential study enrolled low-immune responder SPK transplant recipients. The prednisone/CNI-free (minimization) group of 22 patients received thymoglobulin followed by sirolimus and reduced-dose CsA. Prednisone was withdrawn on day 5, and recipients were converted from CsA to mycophenolic acid at 6 months posttransplantation. The sirolimus/CsA group of 20 consecutive recipients transplanted immediately before this series received thymoglobulin followed by sirolimus, reduced-dose CsA, and prednisone. Results. Donor and recipient demographic variables were equivalent between groups. The 24-month actual patient, kidney, and pancreas survivals for the minimization group were 100%, 100%, and 91% vs. 100%, 95%, and 95% for the sirolimus/CsA group (P=not significant [NS] for patient, kidney, and pancreas survivals). One acute rejection occurred in the minimization group and none in the sirolimus/CsA group. After withdrawal of CsA at 6 months, the minimization group showed an increase in mean estimated glomerular filtration rate, resulting in a significant improvement in renal function compared with the sirolimus/CsA group. At 24 months, the mean glomerular filtration rate of the minimization and sirolimus/CsA groups was 71.6±11.2 mL/min/1.73 m2 and 60.1±13.4 mL/min/1.73 m2, respectively (P<0.05). Mean fasting blood glucose levels were equivalent between groups at all time points studied. Conclusion. Low-immune responder SPK recipients receiving a prednisone/CNI-free protocol achieved similar 2-year graft survivals and improved renal function compared with those treated with a sirolimus, CsA, and prednisone regimen.

[1]  A. Secchi,et al.  Rapamycin in islet transplantation: friend or foe? , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  P. Friend,et al.  Alemtuzumab Induction and Steroid‐Free Maintenance Immunosuppression in Pancreas Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  H. Podder,et al.  Selective corticosteroid and calcineurin‐inhibitor withdrawal after pancreas–kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy , 2008, Clinical Transplantation.

[4]  A. Miki,et al.  Anti-Proinflammatory Effects of Sirolimus on Human Islet Preparations , 2008, Transplantation.

[5]  A. Webster,et al.  Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.

[6]  R. Pelletier,et al.  Steroid-Free Maintenance Immunosuppression With Rapamune and Low-Dose Neoral in Pancreas Transplant Recipients , 2007, Transplantation.

[7]  E. Thervet,et al.  Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  D. Kaufman,et al.  Long-Term Renal Transplant Function in Recipient of Simultaneous Kidney and Pancreas Transplant Maintained With Two Prednisone-Free Maintenance Immunosuppressive Combinations: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus , 2007, Transplantation.

[9]  O. Korsgren,et al.  Effects of Immunosuppressive Drugs on In Vitro Neogenesis of Human Islets: Mycophenolate Mofetil Inhibits the Proliferation of Ductal Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  D. Kaufman,et al.  Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Simultaneous Pancreas‐Kidney Transplantation Comparison With Rabbit Antithymocyte Globulin Induction – Long‐Term Results , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  M. Simmonds,et al.  Alemtuzumab Induction and Sirolimus Plus Mycophenolate Mofetil Maintenance for CNI and Steroid‐Free Kidney Transplant Immunosuppression , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  R. Hirose,et al.  Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. , 2004, Transplantation proceedings.

[13]  T. Pruett Over 500 Solitary Pancreas Transplants in Nonuremic Patients with Brittle Diabetes Mellitus , 2009 .